Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen
Immunology · 2024-07 · 172 (3) · 375-391
DOI: 10.1111/imm.13777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunology, online erschienen am 12.03.2024. Verfasst von Xiaoxuan Li und 15 weiteren Autor:innen. Beteiligte Einrichtung: Obstetrics and Gynecology Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Papillomavirus Infections, Papillomavirus E7 Proteins, Cancer Vaccines, Oncogene Proteins, Viral. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shanghai Virogin Biotech Co., Ltd.
Abstract (Originalsprache)
Persistent human papillomavirus (HPV) infection is associated with multiple malignancies. Developing therapeutic vaccines to eliminate HPV‐infected and malignant cells holds significant value. In this study, we introduced a lipid nanoparticle encapsulated mRNA vaccine expressing tHA‐mE7‐mE6. Mutations were introduced into E6 and E7 of HPV to eliminate their tumourigenicity. A truncated influenza haemagglutinin protein (tHA), which binds to the CD209 receptor on the surface of dendritic cells (DCs), was fused with mE7‐mE6 in order to allow efficient uptake of antigen by antigen presenting cells. The tHA‐mE7‐mE6 (mRNA) showed higher therapeutic efficacy than mE7‐mE6 (mRNA) in an E6 and E7 + tumour model. The treatment resulted in complete tumour regression and prevented tumour formation. Strong CD8 + T‐cell immune response was induced, contributing to preventing and curing of E6 and E7 + tumour. Antigen‐specific CD8 + T were found in spleens, peripheral blood and in tumours. In addition, the tumour infiltration of DC and NK cells were increased post therapy. In conclusion, this study described a therapeutic mRNA vaccine inducing strong anti‐tumour immunity in peripheral and in tumour microenvironment, holding promising potential to treat HPV‐induced cancer and to prevent cancer recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Obstetrics and Gynecology Center, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
- Obstetrics and Gynecology, Shunde Hospital, The First People's Hospital of Shunde, Southern Medical University, Foshan, Guangdong, China.
- Shanghai Virogin Biotech Co., Ltd, Shanghai, China.
- Virogin Biotech Canada Ltd, Vancouver, Canada.
ORCID-Profile: Xiaomei Liang, Yifeng Wang
Förderung
- National Natural Science Foundation of China
- Shanghai Virogin Biotech Co., Ltd
Zitieren
APA
Li, X., Wang, H., Lai, W., Liao, J., Mo, W., Huang, K., He, L., Liang, X., Yu, Z., Xu, J., Hua, X., Hou, F., Ding, J., Jia, W. W., Zhang, K., & Wang, Y. (2024). Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen. Immunology, 172(3), 375-391. https://doi.org/10.1111/imm.13777
Vancouver
Li X, Wang H, Lai W, Liao J, Mo W, Huang K, et al. Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen. Immunology. 2024;172(3):375-391. doi:10.1111/imm.13777
BibTeX
@article{Li2024,
author = {Li, Xiaoxuan and Wang, Huiyan and Lai, Wujiang and Liao, Jinrong and Mo, Wenyu and Huang, Keke and He, Liqing and Liang, Xiaomei and Yu, Zhibin and Xu, Jiang and Hua, Xianwu and Hou, Fujun and Ding, Jun and Jia, William Wei-Guo and Zhang, Kuan and Wang, Yifeng},
title = {Prevention and treatment of HPV‐related cancer through a mRNA vaccine expressing APC‐targeting antigen},
journal = {Immunology},
year = {2024},
volume = {172},
number = {3},
pages = {375--391},
doi = {10.1111/imm.13777}
}
EUVIMED